Full Press Release Details
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):
The presentations will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section athttps://investors.betabionics.com, and will be archived there for future replay following the events.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visitwww.betabionics.com.
Investor Relations:Blake BeberHead of Investor Relationsir@betabionics.com
Media and Public Relations:Karen HynesVice President of Marketingmedia@betabionics.com
Source: Beta Bionics, Inc.